Kymera: a systematic approach to protein degradation

Kymera goes beyond empirical approach to protein degradation with Pegasus platform

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders.

Protein degradation is entering the mainstream as a new modality that can direct medicines at proteins often seen as "undruggable,” such as transcription factors, scaffolds in protein complexes and signaling adaptor molecules.

Kymera's heterobifunctional molecules bind to both an E3 ubiquitin ligase and a target protein, leading to poly-ubiquitination and degradation of the

Read the full 799 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE